Categories Earnings, Health Care
Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot
— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.
— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected
— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year
— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine
— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer
— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020
— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
LLY Earnings: Eli Lilly Q4 2024 profit more than doubles; revenue up 45%
Eli Lilly and Company (NYSE: LLY) Thursday reported a sharp increase in its fourth-quarter revenues. The pharmaceutical company's adjusted earnings more than doubled during the quarter. Worldwide revenue increased 45%
Ford Motor Company (F) Earnings: 4Q24 Key Numbers
Ford Motor Company (NYSE: F) reported revenue of $48.2 billion for the fourth quarter of 2024, up 5% year-over-year. GAAP net income was $1.8 billion, or $0.45 per share, compared
Philip Morris (PM) Q4 2024 Earnings: Key financials and quarterly highlights
Philip Morris International Inc. (NYSE: PM) reported its fourth quarter 2024 earnings results today. Net revenues increased 7.3% year-over-year to $9.7 billion. Organic revenue growth was also 7.3%. Net loss attributable